ライフサイエンスコーパス: vasculitis

1 serum creatinine concentration attributed to vasculitis).

2 such as hypertension, stroke, thrombosis and vasculitis.

3 at which time all had a clinical response of vasculitis.

4 are acute febrile illness due to multi-organ vasculitis.

5 arteritis (GCA), a polygenic immune-mediated vasculitis.

6 s; histological findings indicated cutaneous vasculitis.

7 milar to vancomycin-induced leukocytoclastic vasculitis.

8 nt vaccine-induced arthritis, dermatitis, or vasculitis.

9 ytes of patients with active ANCA-associated vasculitis.

10 th the endothelium, resulting in necrotizing vasculitis.

11 dependent venous congestion and inflammatory vasculitis.

12 sphagia, pronounced muscle fiber damage, and vasculitis.

13 reatment or even as a trigger for rheumatoid vasculitis.

14 roid therapy and sustain chronic, smoldering vasculitis.

15 taneous inflammation, e.g., leukocytoclastic vasculitis.

16 tineutrophil cytoplasmic antibody-associated vasculitis.

17 recurrent stroke to systemic vasculopathy or vasculitis.

18 matosis with polyangiitis is an eosinophilic vasculitis.

19 tis nodosa and one patient with small-vessel vasculitis.

20 vidence of glandular atrophy and necrotizing vasculitis.

21 atherosclerosis, aneurysms, dissections, and vasculitis.

22 etinitis and poor in patients with occlusive vasculitis.

23 therapeutic relevance in atherosclerosis and vasculitis.

24 llularly, and the disease is fundamentally a vasculitis.

25 he underlying cause and pathogenesis of ANCA vasculitis.

26 fibrosis, leukemia, histiocytic sarcoma, and vasculitis.

27 -proven renal involvement of ANCA-associated vasculitis.

28 es, lymphadenopathy, glomerulonephritis, and vasculitis.

29 clinical manifestations due to small-vessel vasculitis.

30 and crescentic glomerulonephritis (NCGN) and vasculitis.

31 arctions, presumed secondary to small vessel vasculitis.

32 stemic lupus erythematosus, and small vessel vasculitis.

33 eded for guiding management of patients with vasculitis.

34 well defined autoantigen in ANCA-associated vasculitis.

35 oproteinase-1, and CXCL13 in ANCA-associated vasculitis.

36 (ANCAs) can result in systemic small vessel vasculitis.

37 most European patients with ANCA-associated vasculitis.

38 vessel vasculitis is the most common primary vasculitis.

39 contribute to the morbidity and mortality of vasculitis.

40 llularly, and the disease is fundamentally a vasculitis.

41 iate disease in experimental ANCA-associated vasculitis.

42 olved in the pathogenesis of ANCA-associated vasculitis.

43 a control group (1022 eyes) with no retinal vasculitis.

44 te of neovascularization relapse in ischemic vasculitis.

45 lacing high-dose glucocorticoids in treating vasculitis.

46 athogenic mechanisms underlying this type of vasculitis.

47 ase characterized by lymphoproliferation and vasculitis.

48 tion revealed peripheral hemorrhagic retinal vasculitis.

49 sk of macular edema compared to eyes with no vasculitis.

50 anti-neutrophil cytoplasmic antibody (ANCA) vasculitis.

51 o being tightly correlated with active renal vasculitis.

52 e inflammatory disease, such as large-vessel vasculitis.

53 linked ADA2 deficiency with inflammation and vasculitis.

54 ts had a serious adverse event or relapse of vasculitis.

55 ted with development of systemic necrotizing vasculitis.

56 early in the disease course of experimental vasculitis.

57 d amount of suprachoroidal fluid on OCT-EDI (vasculitis, 0.45 [P < .001]; vitreous haze, 0.59 [P < .0

58 s (4), eosinophils (4), neutrophils (1), and vasculitis (1).

59 rders (1.32; 95% CI, 1.16-1.50) and systemic vasculitis (1.29; 95% CI, 1.16-1.44).

60 ities were commonly noted: retinal occlusive vasculitis (21/77; 27%) and serpiginoid choroiditis (11/

61 omatous optic atrophy eyes (7.9%) (1 retinal vasculitis, 3 papilledema, 2 infiltrative optic neuropat

62 The most common causes included vasculitis (34.6%) and hematologic disorders (27.4%).

63 vitreous haze (523 of 1153 [45.4%]), retinal vasculitis (374 of 874 [42.8%]), and choroidal involveme

64 sence of >/=1 peripheral granulomas (57.1%), vasculitis (57.1%), vitreoretinal traction (57.1%), and

65 ic autoimmune disorders (7472), and systemic vasculitis (6283) and in 373 851 matched controls.

66 patients with active autoantibody-associated vasculitis, a chronic relapsing autoimmune inflammatory

67 In patients with severe ANCA-associated vasculitis, a single course of rituximab was as effectiv

68 The differences between PR3-ANCA-associated vasculitis (AAV) and MPO-AAV described in the past have

69 ophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) constitutes life-threatening autoimmune

70 ANCA-associated vasculitis (AAV) is a highly inflammatory condition in w

71 murine myeloperoxidase (MPO)-ANCA-associated vasculitis (AAV) show mast cells degranulate, thus enhan

72 emission-induction in severe ANCA-associated vasculitis (AAV), but renal outcomes are unknown.

73 antineutrophil cytoplasm antibody-associated vasculitis (AAV), high-dose glucocorticoid and cyclophos

74 proteinase-3 (PR3)-positive ANCA-associated vasculitis (AAV).

75 athogenesis in patients with ANCA-associated vasculitis (AAV).

76 tineutrophil cytoplasmic antibody-associated vasculitis (AAV).

77 ase activity or worsening, with a Birmingham Vasculitis Activity Score >0, and involvement of one or

78 etrospectively assigned using the Paediatric Vasculitis Activity Score (PVAS) instrument.

79 s achieving a >/=50% reduction in Birmingham Vasculitis Activity Score by week 12 and no worsening in

80 The mean (+/-standard deviation) Birmingham Vasculitis Activity Score decreased from 5.41 (+/-3.53)

81 fied and weighted adoption of the Birmingham Vasculitis Activity Score.

82 ete remission (CR) was defined as Birmingham Vasculitis Activity Score/Wegener's Granulomatosis (BVAS

83 is an acute, inflammatory, and self-limited vasculitis affecting infants and young children.

84 However, advances in the management of vasculitis allow for accurate diagnosis, risk stratifica

85 n implicated in promoting the development of vasculitis, although little is known regarding the mecha

86 Acute Multifocal Hemorrhagic Retinal Vasculitis (AMHRV) is a rare disease with unknown incide

87 In patients with GN or vasculitis, ANCAs are directed against proteinase 3 (PR3

88 sease (KD) is the most common cause of acute vasculitis and acquired cardiac disease in US children.

89 oma there was a partial clinical response of vasculitis and approximately 50% decrease of cryocrit, a

90 are common in patients with primary systemic vasculitis and are seen in vasculitis secondary to disor

91 ed studies on primary central nervous system vasculitis and autoimmune encephalitis and utilizes key

92 ent with urticarial rash, such as urticarial vasculitis and autoinflammatory disorders.

93 tic fibrosis bronchiectasis, ANCA-associated vasculitis and bronchiectasis.

94 oimmune and inflammatory disorders including vasculitis and cardiovascular and Parkinson's diseases,

95 To review the association of thrombosis and vasculitis and discuss some of the proposed causal mecha

96 underlies the development of ANCA-associated vasculitis and GN, but the mechanisms underlying this lo

97 tic benefit in patients with ANCA-associated vasculitis and GN.

98 well as clear histopathology of necrotizing vasculitis and hemorrhage in the brain.

99 titis, inflammatory bowel diseases, systemic vasculitis and HIV infection, as well as chemotherapy an

100 Vasculitis and IgG4 plasma cells were not observed.

101 Patients with retinal vasculitis and low-grade vitritis with or without macula

102 The kinin system is activated during vasculitis and may contribute to chronic inflammation.

103 he concept that proteinase 3 ANCA-associated vasculitis and myeloperoxidase ANCA-associated vasculiti

104 cells by ANCA is central to ANCA-associated vasculitis and necrotizing crescentic glomerulonephritis

105 ANCA-activated phagocytes cause vasculitis and necrotizing crescentic GN (NCGN).

106 ivided into two groups-nerve large arteriole vasculitis and nerve microvasculitis-on the basis of the

107 l therapeutic candidate for Kawasaki disease vasculitis and other IL-1 mediated inflammatory diseases

108 y or trauma, and with negative screening for vasculitis and other systemic autoimmune disease were in

109 ntiferon were diverse, but retinal occlusive vasculitis and serpiginoid choroiditis were common.

110 aques of the coronary arteries, small vessel vasculitis and small aneurysm.

111 epitopes in the pathology of ANCA-associated vasculitis and suggest that autoantibody diversity may b

112 pe recognized by ANCA in patients with acute vasculitis and the nephritogenic murine T cell MPO epito

113 rized by necrotizing small- to medium-vessel vasculitis and the presence of anti-neutrophil cytoplasm

114 ting the visual outcome in eyes with retinal vasculitis and the rate of neovascularization relapse in

115 scuss all drug culprits associated with ANCA vasculitis and then focus on clinical, serologic, therap

116 g to bacterial and blood thrombi, infectious vasculitis and vascular leakage.

117 of disease activity measured in this study (vasculitis and vitreous haze) also showed a significant

118 re easily assessed clinical features such as vasculitis and vitreous haze.

119 had no focal retinal lesions but manifested vasculitis and vitritis.

120 pillary leakage and ischemia, (3) peripheral vasculitis, and (4) leakage from neovascularization.

121 ophil cytoplasmic antibody (ANCA)-associated vasculitis, and a pair of urinary proteins that are elev

122 el associates very tightly with active renal vasculitis, and assessing this level may be a noninvasiv

123 EGPA shows tissue eosinophilia, necrotizing vasculitis, and eosinophil-rich granulomatous inflammati

124 Histopathology revealed leptomeningitis, vasculitis, and focal inflammation in the central nervou

125 of cocaine in any patient with presumed ANCA vasculitis, and if positive, then urine should also be t

126 ips exist between peripheral vessel leakage, vasculitis, and ischemia, it was only macular ischemia a

127 systemic inflammation, lymphoid hyperplasia, vasculitis, and kidney disease.

128 are a therapeutic target in ANCA-associated vasculitis, and suggest that a molecular hotspot within

129 tly detected in ANCA-associated small-vessel vasculitis, and this association prompted us to test whe

130 the diagnosis and management of large vessel vasculitis, and to explore its relationship to atheroscl

131 retinal involvement interpreted as "retinal vasculitis," and improvement of neuroimaging abnormaliti

132 Although cases frequently mimicked vasculitis, angiography was uniformly negative, and spin

133 sculitis and myeloperoxidase ANCA-associated vasculitis are distinct autoimmune syndromes.

134 ons for Acute Multifocal Hemorrhagic Retinal Vasculitis are oral corticosteroids, intravitreal gancic

135 rg-Strauss, EGPA) is a systemic small-vessel vasculitis associated with asthma and eosinophilia.

136 mbranoproliferative GN, lupus nephritis, and vasculitis associated with HRs (95% confidence intervals

137 levels as predictors of aseptic lymphocytic vasculitis-associated lesion (ALVAL) score at histologic

138 Retinal vasculitis at presentation occurred in 61 eyes (26.3%),

139 vitreous hemorrhage has a diverse etiology, vasculitis being the most common cause in our series.

140 Atherosclerosis and vasculitis both feature inflammation mediated by neutrop

141 to categorize patients with ANCA-associated vasculitis, but adding the percentage of normal glomerul

142 ident case was diagnosed as leukocytoclastic vasculitis by tissue examination.

143 nvasively detect and confirm inflammation in vasculitis by using a murine model of Kawasaki disease.

144 imarily a retinitis, choroiditis, or retinal vasculitis; by whether it is paucifocal or multifocal; a

145 SA/C vasculitis can begin as early as NA, but can occur/persi

146 The extent of peripheral vasculitis, capillary nonperfusion, and vessel leakage w

147 l disease, febrile attacks, and small-vessel vasculitis characteristic of Behcet disease.

148 Giant-cell arteritis (GCA) is a large-vessel vasculitis characterized by immune cell infiltration, ye

149 (HCV)-associated mixed cryoglobulinemia (MC) vasculitis commonly regresses upon virus eradication, bu

150 n loss was significantly more in the retinal vasculitis compared with the non-vasculitis group (hazar

151 revealed that patients with ANCA-associated vasculitis could be divided into two groups, on the basi

152 (HCV) infection, and overt cryoglobulinemia vasculitis (CryoVas) develops in approximately 15% of pa

153 rum from patients with acute ANCA-associated vasculitis disrupted blood flow in the chicken chorioall

154 antigen in childhood central nervous system vasculitis; eotaxin-3 and other markers related to eosin

155 schemia increased the risk of vision loss in vasculitis eyes by 4.4 times.

156 To identify novel biomarkers of renal vasculitis flare, we analysed the longitudinal urinary m

157 fic biomarker that can separate active renal vasculitis from other causes of renal dysfunction is lac

158 typical PDNS lesions, including necrotizing vasculitis, glomerulonephritis, granulomatous lymphadeni

159 the retinal vasculitis compared with the non-vasculitis group (hazard ratio [HR] 1.67, 95% confidence

160 he risk of macular edema compared to the non-vasculitis group.

161 s post-immunisation, we found that rats with vasculitis had a significantly different urinary metabol

162 atients with SVV, patients with active renal vasculitis had markedly higher urinary sCD163 levels tha

163 st mortality rates and patients with IgAN or vasculitis had the lowest allograft failure rates.

164 Retinal vasculitis had twice the risk of macular edema compared

165 Remission of vasculitis has been associated with viral clearance, but

166 The incidence of rheumatoid vasculitis has declined significantly in the past severa

167 sibility of biologic therapy in large vessel vasculitis has emerged.

168 h hepatitis C virus-induced cryoglobulinemia vasculitis (HCV-CV).

169 port a case of hemorrhagic occlusive retinal vasculitis (HORV) after prophylactic intracameral vancom

170 nd outcomes of hemorrhagic occlusive retinal vasculitis (HORV).

171 pus nephritis (HR, 0.69; 95% CI, 0.66-0.71), vasculitis (HR, 0.66; 95% CI, 0.61-0.70), DN (HR, 0.50;

172 upus nephritis [HR,0.91; 95% CI, 0.86-0.97], vasculitis [HR, 0.85; 95% CI, 0.76-0.94), DN [HR, 0.73;

173 suffering from immune complex (IC)-mediated vasculitis (ICV).

174 ation occurred in 61 eyes (26.3%), occlusive vasculitis in 59 eyes (25.4%), and macular edema in 42 e

175 e the mechanisms of chronic inflammation and vasculitis in a child lacking IL-17RA and ADA2 to identi

176 ogic analysis of the skin showed necrotizing vasculitis in biopsy samples from 40 of 50 children.

177 lyangiitis, or renal-limited ANCA-associated vasculitis in complete remission after a cyclophosphamid

178 arteritis (GCA) is the most common systemic vasculitis in elderly individuals.

179 l arteritis (GCA) is the most common form of vasculitis in individuals older than 50 years in Western

180 as autoinflammatory syndromes and urticarial vasculitis in patients with recurrent wheals and bradyki

181 zed by hemorrhagic necrosis and neutrophilic vasculitis in the graft without preformed, high titer an

182 gnificantly reduced scores for tubulitis and vasculitis in the grafts of these recipients.

183 d mesenteric polyarteritis-nodosa (PAN)-like vasculitis in their life span, some as early as 4 months

184 Kawasaki disease (KD) is an acute pediatric vasculitis in which host genetics influence both suscept

185 ls from patients with active ANCA-associated vasculitis, indicating that increased transcription resu

186 ent with severe WAS manifesting as cutaneous vasculitis, inflammatory arthropathy, intermittent polyc

187 aglandular systemic complications of SS (ie, vasculitis, interstitial nephritis) were also more commo

188 Hemorrhagic occlusive retinal vasculitis is a rare, potentially devastating condition

189 tineutrophil cytoplasmic autoantibody (ANCA) vasculitis is a systemic autoimmune disease resulting in

190 In conclusion, our study suggests that IgA vasculitis is an archetypal HLA class II disease.

191 SA/C vasculitis is an asynchronous process that can commence

192 ANCA-associated vasculitis is an autoimmune condition characterized by v

193 Retinal vasculitis is associated with an increased risk of visio

194 d (ANCA-associated) small vessel necrotizing vasculitis is caused by immune-mediated inflammation of

195 closely considered in any patient where ANCA vasculitis is entertained given the wide use of these dr

196 genetic component of Immunoglobulin-A (IgA) vasculitis is still far to be elucidated.

197 Large vessel vasculitis is the most common primary vasculitis.

198 ANCA-associated vasculitis is the most frequent cause of crescentic GN.

199 Rheumatoid vasculitis is the most serious extra-articular complicat

200 ophil cytoplasmic antibody (ANCA)-associated vasculitis is unknown.

201 rent biomarkers of renal disease in systemic vasculitis lack predictive value and are insensitive to

202 ions on clinical examination but had retinal vasculitis, low-grade to moderate vitritis, and hypocyan

203 eritis (TAK) are major forms of large-vessel vasculitis (LVV) that share clinical features.

204 standing of the pathogenesis of large-vessel vasculitis may broaden our currently limited therapeutic

205 present a case of biopsy-proven lymphocytic vasculitis mimicking a brain tumor on neuroimaging that

206 1 peptide S-7 improved survival in the MHV68 vasculitis model, whereas an inverse S-7 peptide was ina

207 rescent formation in a renal ANCA-associated vasculitis model.

208 Kawasaki disease is a vasculitis most commonly afflicting children <5 years of

209 s trigger of paralyzing systemic necrotizing vasculitis most severely affecting skeletal muscle, driv

210 (n = 8, 12%), idiopathic peripheral retinal vasculitis (n = 4, 6%), familial exudative vitreoretinop

211 ), autoimmune hemolytic anemia (n = 15), and vasculitis (n = 6).

212 subsequently excluded (n=17), and history of vasculitis (n=11).

213 ed with controls (n=15), patients with acute vasculitis (n=12) had markedly higher levels of circulat

214 leukocytes of patients with ANCA-associated vasculitis observed longitudinally (n=82) and of healthy

215 case of Acute Multifocal Hemorrhagic Retinal Vasculitis occurring in a child.

216 e affected in PR3-AAV, whereas renal limited vasculitis occurs more often in patients with MPO-AAV.

217 Kawasaki disease is an acute, self-limited vasculitis of childhood that can result in structural da

218 Kawasaki disease is an acute vasculitis of childhood that leads to coronary artery an

219 lein Purpura (HSP) is the commonest systemic vasculitis of childhood typically presenting with a palp

220 Kawasaki disease (KD) is the most recognized vasculitis of childhood.

221 olyarteritis nodosa is a form of necrotizing vasculitis of small and medium-sized arteries.

222 Lymphocytic vasculitis of the central nervous system is an uncommon

223 ll, which may participate in the necrotizing vasculitis of the kidney during this disease.

224 To simplify the approach to patients with vasculitis of the peripheral nerves, a straightforward,

225 emorrhage, and is especially associated with vasculitis of the skin, but the mechanisms that regulate

226 Kawasaki disease is an acute, self-limited vasculitis of unknown etiology that occurs predominantly

227 he overall 100% rate of clinical response of vasculitis, on an intention-to-treat basis, opens the pe

228 adult patients presenting with undefined CNS vasculitis or a leukodystrophy with prominent neuropsych

229 fluorescein angiography evidence of retinal vasculitis or papillitis, indocyanine green angiography

230 edictors, therapy and outcomes of rheumatoid vasculitis over the past decade.

231 ediate or panuveitis (P < 0.001), absence of vasculitis (P < 0.001), and a starting dose >/=5 mg/kg (

232 1), as well as beneficial effects in retinal vasculitis (P = .0001) and retinitis (P = .001) were evi

233 308 IgA vasculitis patients and 1,018 healthy controls from Spai

234 ients with: anti-PR3 positive renal and lung vasculitis; patients with non-vasculitic renal disease;

235 mice, injection of CAWS did not result in a vasculitis phenotype, implying a key role of the imaging

236 tineutrophil cytoplasmic antibody-associated vasculitis, polymyositis/dermatomyositis, and primary Sj

237 ix consecutive patients with ANCA-associated vasculitis, positive for either proteinase 3 (PR3)-ANCA

238 retinopathy, inflammatory occlusive retinal vasculitis, post-H1N1 vaccine, hypertensive retinopathy,

239 icles in the pathogenesis of ANCA-associated vasculitis, potentially providing a target for future th

240 Six of 14 patients had vasculitis pre-HSCT.

241 nosis, location of inflammation, presence of vasculitis, prior immunomodulatory treatments, duration

242 ated leakage (r = 0.462, P = .001) and focal vasculitis (r = 0.441, P = .001).

243 icipants in the Rituximab in ANCA-Associated Vasculitis (RAVE) trial were excluded from this analysis

244 nrolled in the Rituximab for ANCA-Associated Vasculitis (RAVE) Trial who had renal involvement (biops

245 al, adults with newly diagnosed or relapsing vasculitis received placebo plus prednisone starting at

246 is, and 5 with renal-limited ANCA-associated vasculitis) received azathioprine (58 patients) or ritux

247 duration of anticoagulation in patients with vasculitis remain unanswered.

248 Rheumatoid vasculitis remains a rare yet challenging extra-articula

249 mol creatinine for detection of active renal vasculitis resulted in a sensitivity of 83%, specificity

250 onset of visual loss associated with retinal vasculitis, retinal hemorrhage, non-confluent posterior

251 cular complications in patients with retinal vasculitis (RV).

252 primary systemic vasculitis and are seen in vasculitis secondary to disorders such as rheumatoid art

253 Patients with symptoms suggestive of this vasculitis should be evaluated for the presence of nonbl

254 aureus and chronic inflammatory disease and vasculitis since early childhood, which were refractory

255 ons with crescents, mimicking a small vessel vasculitis such as ANCA-associated GN, are a very rare m

256 lnerable to NK cell injury during autoimmune vasculitis, such as granulomatosis with polyangiitis (GP

257 bservations in patients with ANCA-associated vasculitis suggest that CD8(+) T cells participate in di

258 ed glomeruli from patients with small vessel vasculitis (SVV) had markedly higher levels of CD163 mRN

259 lating cryoglobulin associated with systemic vasculitis symptoms.

260 i-neutrophil cytoplasmic antibody-associated vasculitis, systemic lupus erythematosus, idiopathic pul

261 3.3 [2.1-6.1]; P=0.01) and in patients with vasculitis than in those referred for other indications.

262 polyangiitis (GPA) is a systemic necrotizing vasculitis that is associated with granulomatous inflamm

263 se in developed countries, is a self-limited vasculitis that is treated with high doses of intravenou

264 Kawasaki disease (KD) is a multisystem vasculitis that predominantly targets the coronary arter

265 MPO-Gd MR imaging helped identify areas of vasculitis that were not seen at unenhanced and contrast

266 However, the unmet need in vasculitis therapy remains large and newer therapies eit

267 from suspected central nervous system (CNS) vasculitis to extrapyramidal to cognitive phenotypes.

268 equelae, ranging from cutaneous and visceral vasculitis to glomerulonephritis and B-cell non-Hodgkin

269 mages were obtained in 63 eyes with ischemic vasculitis to quantify area of nonperfusion measured as

270 b versus Cyclophosphamide in ANCA-Associated Vasculitis trial.

271 ere performed to rule out vitreitis, retinal vasculitis, vitreous hemorrhage, and systemic amyloidosi

272 Vasculitis was also observed in other organs of eNOS-def

273 he use of systemic prednisolone in eyes with vasculitis was associated with a reduced risk of vision

274 In all the families, vasculitis was caused by recessive mutations in CECR1, t

275 Relapse of vasculitis was observed in 1 patient (1.5%) after comple

276 Retinal vasculitis was observed in 16 of 22 eyes (73%) and inclu

277 Retinal vasculitis was observed in 236 eyes (121 ischemic, 115 n

278 al classification system for ANCA-associated vasculitis was recently published, but whether this syst

279 stopathology indicated that leukocytoclastic vasculitis was the central step in dissemination of B. p

280 Bilateral panuveitis associated with retinal vasculitis was the most common manifestation.

281 t knowledge on the genetic component of this vasculitis we performed the first genome-wide associatio

282 ession and disease status in ANCA-associated vasculitis, we measured gene-specific DNA methylation of

283 of macular edema, vitreous haze, and retinal vasculitis were graded; a second grading scale was devel

284 ts with polyarteritis nodosa or small-vessel vasculitis were homozygous for the p.Gly47Arg mutation.

285 eral neuropathy, interstitial nephritis, and vasculitis were more common in those with vision-threate

286 igns, retinitis, neuroretinitis, and retinal vasculitis were seen in this population.

287 ost altered in rats with active or relapsing vasculitis were trimethylamine N-oxide (TMAO), citrate a

288 st anatomic and visual outcomes were seen in vasculitis, whereas congenital disorders such as retinos

289 lateral Acute Multifocal Hemorrhagic Retinal Vasculitis, which later on progressed bilaterally.

290 ggest that RA patients exhibit a subclinical vasculitis, which provides a mechanism for the increased

291 ld with Acute Multifocal Hemorrhagic Retinal Vasculitis who was treated with aggressive immunosuppres

292 Behcet disease (BD) is a systemic vasculitis with a broad range of organ involvement, char

293 Takayasu's arteritis (TAK) is a large-vessel vasculitis with a chronic, indolent course affecting the

294 lyarteritis nodosa is a systemic necrotizing vasculitis with a pathogenesis that is poorly understood

295 with polyangiitis (EGPA) is a rare systemic vasculitis with a prevalence rate of seven per million.

296 severe Acute Multifocal Hemorrhagic Retinal Vasculitis with aggressive immunosuppressive agents in c

297 are two major autoantigens in patients with vasculitis with ANCA.

298 association of hemorrhagic occlusive retinal vasculitis with vancomycin and the commercial unavailabi

299 osuppurative to granulomatous meningitis and vasculitis, with thrombi and abundant angioinvasive fung

300 s with mild to moderate vitritis and retinal vasculitis without definite birdshot lesions on clinical